Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna's Covid-19 Vaccine Seeks FDA Authorization for Use in Adolescents

06/10/2021 | 11:36am EDT

By Peter Loftus

Moderna Inc. said Thursday it has asked U.S. health regulators to authorize the use of its Covid-19 shot in adolescents ages 12 to 17, setting up the potential availability of a second vaccine option for adolescents.

The application means Moderna's vaccine could be cleared for use in the older children this summer.

Moderna is seeking authorization from the U.S. Food and Drug Administration after releasing results of a study in May showing that the vaccine safely induced immune response in adolescents and appeared to be protective against Covid-19 disease.

"We are encouraged that the Moderna Covid-19 vaccine was highly effective at preventing Covid-19 and SARS-CoV-2 infection in adolescents, " Moderna Chief Executive Stephane Bancel said.

The FDA could make a decision on Moderna's request by early July if it follows the same kind of timetable if took with the Covid-19 vaccine from Pfizer Inc. and BioNTech SE.

The agency took about a month to clear Pfizer's request for use of its Covid-19 vaccine in 12- to 15-year-olds in May.

Moderna's vaccine is currently authorized for use in adults ages 18 and older, as is one from Johnson & Johnson. Pfizer's vaccine was initially cleared in people 16 years and older before the FDA expanded use.

Pfizer and Moderna also are studying their shots in children younger than age 12. The companies said this week initial results from that testing could be available by the fall.

Positive results could clear the way for regulators to authorize use of the shots in younger children before the end of the year.

Moderna's request is part of a wider push to expand the mass vaccination campaign to children, after initially focusing on adults.

Though children have lower risk than adults of severe complications from Covid-19, infectious-disease specialists say some can develop serious illness. They say it's important to vaccinate children to protect them individually, as well as build herd immunity that can allow everyone to return to a more normal life.

About seven million adolescents have received at least one does of a Covid-19 vaccine in the U.S., according to the U.S. Centers for Disease Control and Prevention.

Moderna earlier this week requested authorization of use of its vaccine in adolescents in Canada and the European Union.

Moderna conducted a Phase 2/3 study of its Covid-19 vaccine in about 3,700 adolescents. The study found that their immune responses were comparable with those from adults who had participated in a separate Phase 3 study of the vaccine in adults. The adult study had shown that the vaccine was 94.1% effective at preventing symptomatic Covid-19.

The Cambridge, Mass., company said the most common side effects among adolescents included injection-site pain, headache and fatigue.

(END) Dow Jones Newswires

06-10-21 1135ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -3.50% 230.2 Delayed Quote.190.10%
DJ INDUSTRIAL -0.04% 33935.28 Delayed Quote.10.91%
JOHNSON & JOHNSON -0.32% 163.105 Delayed Quote.3.96%
MODERNA, INC. -5.37% 211.9167 Delayed Quote.111.89%
PFIZER, INC. -1.16% 39.2 Delayed Quote.7.61%
All news about MODERNA, INC.
01:19pStocks Mixed Midday as Defensives Trade Lower; Oil Advances as Crude Stockpil..
01:04pMIDDAY REPORT : US Stocks Mixed as Defensives Trade Lower; Oil Advances as Crude..
12:02pMODERNA  : 'Likely link' between rare heart inflammation and Pfizer, Moderna vac..
11:49aUS' CDC To Study Possible Link Between Heart Inflammation And Pfizer/BioNTech..
10:39aGSK's drugs arm to get $11 billion booster from consumer spin-off
10:17aMODERNA  : European Commission Purchases Additional 150 Million Doses of Moderna..
08:58aMODERNA  : Japan to halt company applications for workplace vaccinations
08:23aMODERNA  : CureVac founder withdraws candidacy for supervisory board
02:11aDebate Intensifies Over A Vaccine IP Waiver's Impact On Future Pharma And Bio..
01:02aSECTORAL ASSET MANAGEMENT  : Covid-Vaccine Patent Waiver: Will it Increase World..
More news
Financials (USD)
Sales 2021 18 632 M - -
Net income 2021 10 719 M - -
Net cash 2021 11 520 M - -
P/E ratio 2021 8,97x
Yield 2021 -
Capitalization 88 882 M 88 882 M -
EV / Sales 2021 4,15x
EV / Sales 2022 4,28x
Nbr of Employees 1 300
Free-Float 90,3%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 221,36 $
Average target price 168,87 $
Spread / Average Target -23,7%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.111.89%88 882
LONZA GROUP AG14.06%52 367
CELLTRION, INC.-21.59%32 903
SEAGEN INC.-9.40%28 797